Archara Supavavej

Archara Supavavej

Auto-generated profile, based on publicly available information

Archara Supavavej

Division of Medical Oncology, Chulabhorn Hospital, Chulabhorn Royal Academy, Bangkok, Thailand

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2023 in JCO Global Oncology
Verified
Journal Article
Open access
WTWalaipan Tantiyavarong
Walaipan Tantiyavarong
PSPrakongboon Sungkasubun
Prakongboon Sungkasubun
WCWorawit Chaiwiriyawong
Worawit Chaiwiriyawong
ASArchara Supavavej
Archara Supavavej
PLPiyarat Limpawittayakul
Piyarat Limpawittayakul
CSChayanee Samdaengpan
Chayanee Samdaengpan
PURPOSE: The COVID-19 pandemic has affected public health worldwide. The efficacy and safety of COVID-19 vaccines have been evaluated in the general population; however, data on patients with malignancies are limited. METHODS: This prospective longitudinal observational cohort study was conducted between June and July 2021. Enrolled adult patients with cancer were divided into chemotherapy and nonchemotherapy groups. All participants were immunized with two doses of the ChAdOx1 nCoV-19 or CoronaVac COVID-19 vaccines. The primary outcome was a comparison of the immunogenicity (as assessed by spike protein [anti-S] immunoglobulin G [IgG] antibody titers) of two doses of COVID-19 vaccine in the chemotherapy and nonchemotherapy groups. The secondary outcomes included the anti-S IgG seroconversion rate and vaccine safety in both groups. RESULTS: Among the 173 enrolled patients with solid cancer, after COVID-19 vaccination, the chemotherapy group had a significantly lower median anti-S IgG titer than the nonchemotherapy group (26 v 237 U/mL, P < .001). A statistically significant difference in anti-S IgG titer was found between groups vaccinated with CoronaVac (7 v 90 U/mL, P < .001), but no difference was found in those vaccinated with ChAdOx1 nCoV-19 (818 v 1061 U/mL, P = .075). The anti-S IgG seroconversion rate was significantly lower in the chemotherapy group than that in the nonchemotherapy group (78.9% v 96.5%, P = .001). No new or serious vaccine-related adverse events were reported. CONCLUSION: Patients with solid cancer receiving a COVID-19 vaccine while undergoing chemotherapy had lower immunogenicity responses to vaccination than those who were vaccinated while undergoing nonchemotherapy treatment. No statistically significant difference was observed in the COVID-19 vaccine safety profiles between groups.

1 January 2025 in International Journal of Breast Cancer
Verified
Journal Article
Open access
TSThiti Susiriwatananont
Thiti Susiriwatananont
CWConcord Wongkraisri
Concord Wongkraisri
TDThanate Dajsakdipon
Thanate Dajsakdipon
ASArchara Supavavej
Archara Supavavej
ADArunee Dechaphunkul
Arunee Dechaphunkul
NPNapa Parinyanitikul
Napa Parinyanitikul
Purpose: HER2‐low status is a predictive factor for novel anti‐HER2 therapies in metastatic hormone receptor–positive breast cancer (HR+ MBC). However, its impact on endocrine therapy outcomes remains uncertain. We aimed to explore the effect of HER2‐low and HER2‐zero status in HR+ MBC patients treated with first‐line aromatase inhibitors (AIs) with or without CDK4/6 inhibitors (CDK4/6i). Methods: We retrospectively reviewed postmenopausal women with HR+ MBC treated with first‐line AI ± CDK4/6i between January 1, 2017, and December 31, 2022, from six tertiary hospitals in Thailand. HER2‐low was defined as HER2 IHC 1+ or IHC 2+ with ISH‐negative. Progression‐free survival (PFS) and overall survival (OS) were compared in unadjusted and adjusted cohorts using stabilized inverse probability of treatment weighting (sIPTW), adjusting for age, ECOG performance status, de novo metastasis, endocrine sensitivity, visceral metastasis, number of metastatic sites, and treatment year. Interaction analyses were performed to assess effect modification by HER2 status and other clinical subgroups. Results: Among 504 patients, 219 (43.5%) were HER2‐low, and 285 (56.5%) were HER2‐zero. Median follow‐up was 31 months (IQR 19–47). CDK4/6i + AI was administered to 52.5% of HER2‐low and 43.9% of HER2‐zero patients. After sIPTW adjustment, CDK4/6i + AI prolonged median PFS to 22.1 months compared with 21.5 months for AI alone in the HER2‐low cohort (HR = 0.80, 95% CI 0.54–1.18; p = 0.26) and to 20.1 months compared with 13.5 months in the HER2‐zero cohort (HR = 0.65, 95% CI 0.45–0.93; p = 0.02). Median OS was 49.3 months with CDK4/6i + AI versus 48.4 months with AI alone in HER2‐low (HR = 0.81, 95% CI 0.48–1.36; p = 0.43) and 45.8 versus 42.3 months in HER2‐zero (HR = 0.85, 95% CI 0.43–1.05; p = 0.52). Subgroup analyses showed consistent benefit of CDK4/6i + AI across most clinical categories. The interaction test for treatment × HER2 status was not significant (HR = 1.21, 95% CI 0.74–1.98; p = 0.44), indicating no effect modification by HER2‐low status. Conclusions: HER2‐low status was not associated with prognosis or predictive value for CDK4/6i efficacy, supporting CDK4/6i + AI as the standard first‐line therapy irrespective of HER2 expression level.

1 May 2024 in JCO Global Oncology
Verified
Journal Article
Closed access
CSChayanee Samdaengpan
Chayanee Samdaengpan
PSPrakongboon Sungkasubun
Prakongboon Sungkasubun
WCWorawit Chaiwiriyawong
Worawit Chaiwiriyawong
ASArchara Supavavej
Archara Supavavej
JSJomtana Siripaibun
Jomtana Siripaibun
PLPiyarat Limpawittayakul
Piyarat Limpawittayakul
PURPOSE: Corticosteroids are known to diminish immune response ability, which is generally used in routine premedication for chemotherapy. The intersecting of timeframe between the corticosteroid's duration of action and peak COVID-19 vaccine efficacy could impair vaccine immunogenicity. Thus, inquiring about corticosteroids affecting the efficacy of vaccines to promote effective immunity in this population is needed. METHODS: This was a prospective longitudinal observational cohort study that enrolled patients with solid cancer classified into dexamethasone- and nondexamethasone-receiving groups. All participants were immunized with two doses of ChAdOx1 nCoV-19 or CoronaVac vaccines. This study's purpose was to compare corticosteroid's effect on immunogenicity responses to the SARS-CoV-2 S protein in patients with cancer after two doses of COVID-19 vaccine in the dexamethasone and nondexamethasone group. Secondary outcomes included the postimmunization anti–spike (S) immunoglobin G (IgG) seroconversion rate, the association of corticosteroid dosage, time duration, and immunogenicity level. RESULTS: Among the 161 enrolled patients with solid cancer, 71 and 90 were in the dexamethasone and nondexamethasone groups, respectively. The median anti–S IgG titer after COVID-19 vaccination in the dexamethasone group was lower than that in the nondexamethasone group with a statistically significant difference (47.22 v 141.09 U/mL, P = .035). The anti–S IgG seroconversion rate was also significantly lower in the dexamethasone group than in the nondexamethasone group (93.83% v 80.95%, P = .023). The lowest median anti–SARS-CoV-2 IgG titer level at 7.89 AU/mL was observed in patients with the highest dose of steroid group (≥37 mg of dexamethasone cumulative dose throughout the course of chemotherapy [per course]) and patients who were injected with COVID-19 vaccines on the same day of receiving dexamethasone, 25.41 AU/mL. CONCLUSION: Patients with solid cancer vaccinated against COVID-19 disease while receiving dexamethasone had lower immunogenicity responses than those who got vaccines without dexamethasone. The direct association between the immunogenicity level and steroid dosage, as well as length of duration from vaccination to dexamethasone, was observed.